SS
TCRR

Simplicity Solutions’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Simplicity Solutions’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-31,530
Closed -$87K – 713
2022
Q1 		$87K Buy
+31,530
New +$99.2K 0.01% 611

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Simplicity Solutions's TCRR Position: Q2 2022 in Review

Simplicity Solutions sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 31,530 shares — an estimated $87K sold.

Simplicity Solutions first reported a position in TCRR in Q1 2022 and held it in 1 quarter. The position peaked at $87K in Q1 2022. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • Simplicity Solutions reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Simplicity Solutions sold 31,530 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $87K.
  • Simplicity Solutions first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Simplicity Solutions's TCR2 Therapeutics Inc. Common Stock position peaked at $87K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on Simplicity Solutions's 13F filing for Q2 2022, filed 19 Jul 2022.